Clinical Trial Update: Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) [Phase 1, Phase 2]

View source ↗

Summary

A sponsor-backed Phase 1/2 clinical trial evaluates the combination of palbociclib and sasanlimab for advanced clear cell renal cell carcinoma and papillary ren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Papillary Renal Cell Carcinoma

Drugs mentioned

• Palbociclib (palbociclib)
• Sasanlimab (sasanlimab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc) | Phase 1, Phase 2 | Status: RECRUITING